Monteris earns FDA approval of MRI-guided laser surgery tool for "inoperable" brain cancer

MAY 18, 2009--Monteris Medical Inc. (Kalamazoo, MI) has received 501(k) clearance from the US Food and Drug Administration (FDA) for use of its AutoLITT System in neurosurgery. The AutoLITT MRI-guided laser surgery method is in investigational use at both The Cleveland Clinic and University Hospitals Case Medical Center. The first applications of the technology are expected to be for the treatment of otherwise inoperable brain tumors.

The system uses an MRI-guided laser probe, passed through a small bur hole in the skull, to deliver laser interstitial thermal therapy ("LITT") to heat and coagulate the tumor from the inside. The probe delivers high-intensity laser energy directly to the tumor, rather than passing through normal tissue, while the MRI measures the temperature inside the brain, showing thermal damage as it happens and facilitating precise control of the treatment. Once coagulated, the treated tumor mass is dead.

"The AutoLITT procedure delivers new-found hope for patients who have previously been given limited options in the treatment of their tumors," said James Duncan, president and CEO of Monteris Medical. The system offers a potential option for patients with tumors that are too difficult or too risky to treat, tumors that don't respond to other treatments, and tumors in patients that are otherwise not good candidates for surgery or radiosurgery.

Monteris is a medical device company focused on developing new cancer treatment technologies that improve clinical outcomes, quality of life, and the cost and complexity of care. The company's U.S. corporate headquarters are in Kalamazoo, Michigan; R&D headquarters are in Winnipeg, Manitoba, Canada.

Learn more about Monteris and AutoLITT at the company's website.

Posted by Barbara G. Goode, barbarag@pennwell.com, for BioOptics World.

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

(SLIDESHOW) View the July/August 2013 issue

ONCOLOGY/CANCER TREATMENT: Study reveals potential of terahertz pulses to fight cancer

Terahertz (THz) photons don't have sufficient energy to break apart the bonds that bind DNA in a cell's nucleus.

OPTOACOUSTICS/OXIMETRY: Real-time photoacoustics beats pulse oximetry by measuring oxygenation in single cells

Red blood cells ferry oxygen to a body's cells and tissues by way of arteries, veins, and capillaries.

SPECTROSCOPY/ONCOLOGY/GYNECOLOGY: First-ever minimally invasive ovarian cancer screen is spectroscopy-based

Researchers at Northwestern University and NorthShore University HealthSystem have previously demonstrated the ability of partial-wave spectroscopy to detect subtle changes in cells that indicate c...

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS